EIF2AK3 and tauopathy: This neuroprotective mechanism occurs independently and downstream to the process of prion propagation and aggregation (Moreno et al., 2013), and noting the activation of UPR in the tauopathies, it is possible that PERK inhibition could present as a therapeutic target in neurodegenerative tauopathies and proteopathies in general.